Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Bionomics (Nasdaq: BNOX), a clinical-stage biotechnology company focused on developing novel allosteric ion channel modulators for serious central nervous system (CNS) disorders, has been invited to present at the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , begins on October 15th, 2024, at 9:00 a.m. ET.
Dr. Spyros Papapetropoulos, President and CEO of Bionomics, will participate in a fireside chat with Maxim's Senior Analysts on October 16th at 10:30 a.m. ET. Interested parties can attend by signing up for M-Vest membership. This presentation provides an opportunity for Bionomics to showcase its progress in developing treatments for CNS disorders with high unmet medical needs.
Bionomics (Nasdaq: BNOX), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di nuovi modulatori allosterici dei canali ionici per gravi disturbi del sistema nervoso centrale (CNS), è stata invitata a presentare al Virtual Summit Maxim Healthcare 2024. L'evento, presentato da Maxim Group, avrà inizio il 15 ottobre 2024 alle 9:00 a.m. ET.
Dr. Spyros Papapetropoulos, Presidente e CEO di Bionomics, parteciperà a una chiacchierata informale con gli analisti senior di Maxim il 16 ottobre alle 10:30 a.m. ET. Le parti interessate possono partecipare registrandosi per diventare membri di M-Vest. Questa presentazione offre a Bionomics l'opportunità di mostrare i propri progressi nello sviluppo di trattamenti per i disturbi del CNS con elevate esigenze mediche insoddisfatte.
Bionomics (Nasdaq: BNOX), una empresa de biotecnología en etapa clínica centrada en el desarrollo de nuevos moduladores alostéricos de canales iónicos para trastornos graves del sistema nervioso central (SNC), ha sido invitada a presentar en el Summit Virtual Maxim Healthcare 2024. El evento, presentado por Maxim Group, comenzará el 15 de octubre de 2024 a las 9:00 a.m. ET.
Dr. Spyros Papapetropoulos, Presidente y CEO de Bionomics, participará en una charla informal con los analistas senior de Maxim el 16 de octubre a las 10:30 a.m. ET. Las partes interesadas pueden asistir registrándose para la membresía de M-Vest. Esta presentación brinda a Bionomics la oportunidad de mostrar su progreso en el desarrollo de tratamientos para los trastornos del SNC con altas necesidades médicas no satisfechas.
바이오노믹스 (Nasdaq: BNOX)는 심각한 중추신경계 (CNS) 장애를 위한 새로운 알로스테릭 이온 채널 조절제를 개발하는 데 중점을 둔 임상 단계의 생명공학 회사입니다. 바이오노믹스는 2024 맥심 헬스케어 가상 정상 회담에 발표하도록 초대되었습니다. 이 행사는 맥심 그룹이 주최하며, 2024년 10월 15일 오전 9시 (ET)에 시작됩니다.
스파이로스 파파페트로폴로스 박사는 10월 16일 오전 10시 30분 (ET)에 맥심의 수석 분석가들과 Fireside Chat에 참여할 예정입니다. 관심 있는 당사자는 M-Vest 회원 가입을 통해 참석할 수 있습니다. 이번 발표는 바이오노믹스가 의료적 필요가 높은 CNS 장애 치료 개발의 진전을 보여줄 수 있는 기회를 제공합니다.
Bionomics (Nasdaq: BNOX), une entreprise de biotechnologie en phase clinique axée sur le développement de nouveaux modulateurs allostériques des canaux ioniques pour des troubles graves du système nerveux central (SNC), a été invitée à présenter lors du Sommet Virtuel Maxim Healthcare 2024. L'événement, présenté par Maxim Group, débutera le 15 octobre 2024 à 9h00 ET.
Dr. Spyros Papapetropoulos, Président et PDG de Bionomics, participera à une discussion informelle avec les analystes seniors de Maxim le 16 octobre à 10h30 ET. Les parties intéressées peuvent assister en s'inscrivant pour devenir membres de M-Vest. Cette présentation offre à Bionomics l'opportunité de mettre en avant ses avancées dans le développement de traitements pour les troubles du SNC avec des besoins médicaux non satisfaits importants.
Bionomics (Nasdaq: BNOX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger allosterischer Ionenkanalmodulatoren für schwerwiegende Störungen des zentralen Nervensystems (ZNS) konzentriert, wurde eingeladen, auf dem 2024 Maxim Healthcare Virtual Summit zu präsentieren. Die Veranstaltung, die von Maxim Group präsentiert wird, beginnt am 15. Oktober 2024 um 9:00 Uhr ET.
Dr. Spyros Papapetropoulos, Präsident und CEO von Bionomics, wird am 16. Oktober um 10:30 Uhr ET an einem informellen Gespräch mit den Senior Analysts von Maxim teilnehmen. Interessierte Parteien können teilnehmen, indem sie sich für eine M-Vest-Mitgliedschaft anmelden. Diese Präsentation bietet Bionomics die Möglichkeit, seine Fortschritte bei der Entwicklung von Behandlungen für ZNS-Störungen mit hohen unerfüllten medizinischen Bedürfnissen zu präsentieren.
- None.
- None.
ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that the Company has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, starting Tuesday, October 15th, 2024, at 9:00 a.m. E.T.
Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will participate in a fireside chat with Maxim’s Senior Analysts on Wednesday, October 16 at 10:30am ET.
To attend, just sign up to become an M-Vest member and stay tuned for more updates.
Click here to reserve your seat
FOR FURTHER INFORMATION PLEASE CONTACT:
| General Rajeev Chandra Company Secretary CoSec@bionomics.com.au | Investor Relations Kevin Gardner kgardner@lifesciadvisors.com | Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com |
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit maximgrp.com
About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other CNS conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need. www.bionomics.com.au.
FAQ
When is Bionomics (BNOX) presenting at the 2024 Maxim Healthcare Virtual Summit?
Who will represent Bionomics (BNOX) at the 2024 Maxim Healthcare Virtual Summit?
How can I attend Bionomics' (BNOX) presentation at the 2024 Maxim Healthcare Virtual Summit?
What is the focus of Bionomics' (BNOX) research and development?
